Navigation Links
Top-line Data From Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results
Date:6/8/2012

V1). The secondary objective was to assess pulmonary exacerbation rates for ataluren compared to placebo. Additional endpoints evaluated other aspects of patient function, drug activity, and safety. The 48-week trial enrolled 238 patients, ages six years and older, at multiple sites in North America, Europe, and Israel. Patients were randomly assigned to one of two treatment arms: ataluren (10 mg/kg morning, 10 mg/kg midday, 20 mg/kg evening) or placebo (morning, midday, evening). Patients who completed the study were eligible to receive open-label ataluren in an ongoing extension study. 

About AtalurenAn investigational new drug, ataluren is a protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation. A nonsense mutation is an alteration in the genetic code that prematurely halts the synthesis of an essential protein. The resulting disorder is determined by which protein cannot be expressed in its entirety and is no longer functional, such as the cystic fibrosis transmembrane conductance regulator protein (CFTR) in nmCF.

The FDA and the European Commission have granted ataluren Orphan Drug status for the treatment of nonsense mutation cystic fibrosis and nonsense mutation Duchenne and Becker muscular dystrophy. The FDA has also granted ataluren Subpart E designation for expedited development, evaluation, and marketing for CF and dystrophinopathy and Fast Track designation for the development of treatment for nonsense mutation dystrophinopathy.

The development of ataluren has been supported by grants from Cystic Fibrosis Foundation Therapeutics Inc. (the nonprofit affiliate of the Cystic Fibrosis Foundation); Muscular Dystrophy Association; FDA's Office of Orphan Products Development; National Center for Research Resources; National Heart, Lung, and Blood Institute; and Parent Project Muscular Dystrophy.

About PTC Therapeutics, Inc.<
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
2. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
3. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
4. Sorrento Therapeutics Awarded Third Phase I STTR Grant
5. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
6. Interim Results Reported for Phase I Open-Label Clinical Trial for the Treatment of PTSD and MDD Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
7. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
8. Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344
9. Preliminary Phase 2 Data of Ocera Therapeutics OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction
10. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
11. Clinilabs Opens Phase I Unit In Eatontown, New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... Physician-Patient Alliance for Health & Safety announced ... the Physician-Patient Alliance Board of Advisors. ... who has practiced in the post-acute care arena since ... on critical patient safety issues. He has represented the ... various conferences addressing the need for patient monitoring and ...
(Date:4/28/2015)... , April 28, 2015  Olympus, a precision technology ... and surgical procedures, among other core businesses, announced today ... Brooklyn Park, MN. The new ... designed to position the company for continued long-term growth ... dedication ceremony took place on April 27 and was ...
(Date:4/28/2015)... , April 28, 2015 A new ... Personal Prescription Importation (CPPI) , has launched today ... prescription medications from Canada ... of Americans – especially the elderly and others ... extremely high price of prescription medications in the ...
Breaking Medicine Technology:Noted Respiratory Therapist and AARC Representative Gene Gantt Joins Physician-Patient Alliance for Health & Safety Advisory Board 2Olympus Opens New Surgical Innovation Center, Positioning Company for Long-term Growth 2Olympus Opens New Surgical Innovation Center, Positioning Company for Long-term Growth 3Olympus Opens New Surgical Innovation Center, Positioning Company for Long-term Growth 4Campaign For Personal Prescription Importation (CPPI), New National Patient Advocacy Organization, Launches Today 2Campaign For Personal Prescription Importation (CPPI), New National Patient Advocacy Organization, Launches Today 3
... The U.S. Food and Drug Administration today is ... that include a new standardized format to improve readability ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Merck,s ... labels for 16 solid oral drug products regulated by ...
... 2011 The U.S. Food and Drug Administration today ... to simultaneously perform a positron emission tomography scan, commonly ... (MRI) scan. (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... how the organs and tissues inside the body are ...
Cached Medicine Technology:FDA Approves Redesigned Labels for Some Merck Drugs 2FDA Clears New System to Perform Simultaneous PET, MRI Scans 2FDA Clears New System to Perform Simultaneous PET, MRI Scans 3
(Date:4/28/2015)... Petersburg, FL (PRWEB) April 28, 2015 ... Health System were named to Becker's Hospital Review’s ... Safety . Peter Pronovost, M.D., Ph.D. , director ... Quality and senior vice president for patient safety ... Mueller, M.D., M.H.C.M. , vice president of medical affairs ...
(Date:4/28/2015)... 2015 The popular all-natural supplement brand, ... their newly launched L-Style Revolution Program™, and collectively the ... in just two short months. The customized weight ... plan for men and women of all health and ... and weight maintenance goals faster than traditional methods. , ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 An ... Blair A. Jobe, MD, FACS , has launched the ... tissue with extracellular matrix (ECM) can help patients who ... of esophageal cancer. , ECM is a complex mixture ... attachment and migration and signals that guide cell behavior. ...
(Date:4/28/2015)... As the Muscular Dystrophy Association continues ... the organization has hired Scientific Program Officer Lianna ... Fidelity Biosciences Research Initiative where, as Associate Director, ... diseases such as Alzheimer’s Disease, and organized and ... Fidelity, she was a junior faculty member at ...
(Date:4/28/2015)... 28, 2015 Researchers from four US ... of a steroid prior to pemetrexed (Alimta) chemotherapy may ... Click here to read the full story ... the Raabe College of Pharmacy in Ohio, Stanford Cancer ... Regional Healthcare in Kentucky gave a single dose of ...
Breaking Medicine News(10 mins):Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 2Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 3Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 4Health News:Sports Nutrition Supplement Brand, Liporidex, Is Making History With Its New L-Style Revolution Diet & Exercise Program Reaching Over 10,000 Pounds Lost In Two Months 2Health News:Sports Nutrition Supplement Brand, Liporidex, Is Making History With Its New L-Style Revolution Diet & Exercise Program Reaching Over 10,000 Pounds Lost In Two Months 3Health News:Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue 2Health News:Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue 3Health News:MDA Adds Neurological Disease Expert to Research Team 2Health News:MDA Adds Neurological Disease Expert to Research Team 3Health News:Study Finds New Regimen May Ward Off Skin Rash from Common Mesothelioma Drug, According to Surviving Mesothelioma 2
... Jersey has its share of underserved children, according to a ... state,s children between 3 and 18 received no dental care ... almost one-third of the state,s children received no care, the ... were still likely to forgo visits to the dentist. ...
... EDITOR,S PICK: Predicting resistance to brain tumor chemotherapy ... lethal of all human brain tumors that originate in ... by both radiation therapy and chemotherapy with temozolomide. However, ... A team of researchers led by Sameer Agnihotri, at ...
... Medicine (BUSM) have identified for the first time the ... target against atherosclerosis resulting from a diet high in ... Circulation , may have significant public health implications. ... at low levels, and at higher levels during exercise ...
... have discovered how malaria manipulates the immune system to allow ... immune system pathway, the research team was able to cure ... published Dec. 11 in the Advance Online Publication of the ... a new approach for treating malaria that does not rely ...
... seedlings is important to crop growth and yield after ... stems, thick leaves, dark green leaves, and large white ... physiology are strongly influenced by the light spectrum, which ... has been shown to increase crop yield after planting ...
... December 11, 2011) Lymphoma and myeloma are both ... blood cells, and commonly involve lymph nodes and the ... the treatment of these diseases, they remain a significant ... unique treatment approaches and targets for lymphoma and myeloma ...
Cached Medicine News:Health News:Rutgers Study: When it comes to use of dental services, not all NJ youngsters are equal 2Health News:Rutgers Study: When it comes to use of dental services, not all NJ youngsters are equal 3Health News:JCI online early table of contents: Dec. 12, 2011 2Health News:JCI online early table of contents: Dec. 12, 2011 3Health News:JCI online early table of contents: Dec. 12, 2011 4Health News:JCI online early table of contents: Dec. 12, 2011 5Health News:JCI online early table of contents: Dec. 12, 2011 6Health News:JCI online early table of contents: Dec. 12, 2011 7Health News:JCI online early table of contents: Dec. 12, 2011 8Health News:JCI online early table of contents: Dec. 12, 2011 9Health News:Researchers identify agent responsible for protection against early stages of atherosclerosis 2Health News:Researchers use new finding to clear bloodstream malaria infection in mice 2Health News:Researchers use new finding to clear bloodstream malaria infection in mice 3Health News:Blue light irradiation promotes growth, increases antioxidants in lettuce seedlings 2Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 2Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 3Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 4Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 5Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 6Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 7Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 8Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 9
... Jenner Stain is used for ... is one of the oldest stain ... provides results similar to that of ... to appear brighter red; basophilic granules ...
Our Reticulocyte Stain is a specialized hematology stain for identifying immature erythrocytes. These immature erythrocytes stain blue in a fine mesh network within the erythrocyte. Mature erythrocyt...
The Buffered Wright Stain is a single solution stain that contains the fixative, buffer, and stain for rapid and convenient staining of blood smears. It is packaged in a 32-oz. bottle for ease of use...
Our Wright stain is a dual-use stain for peripheral blood and bone marrow smears. It produces results similar to those of the Giemsa stain with a slightly greater contrast....
Medicine Products: